Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA | P62937 | 3/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | STAT6 | P42226 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP10 | P09238 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6159606 | 0.85 | OPRM1 (0.42) | OPRM1ALDH1A1 | |
| SCHEMBL6160228 | 0.84 | CYP1A2 (0.33) | CYP1A2ALDH1A1 | |
| SCHEMBL6158568 | 0.83 | HSD11B1 (0.37) | PPIAHSD11B1NR1H2NR1H3 | |
| SCHEMBL8913135 | 0.82 | KMT2A (0.31) | CYP1A2CYP3A4 | |
| SCHEMBL6159543 | 0.81 | PPIA (0.34) | PPIACYP1A2CYP3A4CYP2C19OPRM1 | |
| SCHEMBL8301187 | 0.81 | KDM4E (0.34) | ALDH1A1TP53MAPT | |
| SCHEMBL8301176 | 0.81 | HTT (0.36) | CYP1A2ALDH1A1 | |
| SCHEMBL16757131 | 0.80 | PPIA (0.41) | PPIAHSD11B1OPRM1ALDH1A1MAPT | |
| SCHEMBL6159570 | 0.80 | MAPT (0.32) | CYP1A2MAPT | |
| SCHEMBL8300377 | 0.80 | FPR3 (0.35) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0739891-B1 | Substituted heterocycles | ASTRAZENECA AB (SE) | 2005-01-19 | — | — | EP | claimed |
| EP-0739891-A2 | Substituted heterocycles | ZENECA LIMITED (GB) | 1996-10-30 | — | — | EP | claimed |
| EP-0739891-B1 | Substituted heterocycles | ASTRAZENECA AB (SE) | 2005-01-19 | — | — | EP | disclosed |
| US-6355695-B1 | ANTIHISTAMINES; ASTHMA THERAPY | ZENECA LIMITED (SE) | 2002-03-12 | — | — | US | disclosed |
| US-6235757-B1 | ANTIHISTAMINES | ZENECA LIMITED (GB) | 2001-05-22 | — | — | US | disclosed |
| US-6051580-A | Substituted heterocycles | ZENECA LIMITED | 2000-04-18 | — | — | US | disclosed |
| EP-0726893-B1 | NOVEL 4-PIPERIDINYL SUBSTITUTED LACTAMES AS NEUROKININ 2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA | ZENECA LTD (GB) | 1999-12-22 | — | — | EP | disclosed |
| US-5889024-A | Substituted heterocycles | ZENECA LIMITED (GB) | 1999-03-30 | — | — | US | disclosed |
| EP-0808303-A1 | 5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1997-11-26 | — | — | EP | disclosed |
| US-5677317-A | Lactam compounds which are useful in the treatment of asthma | ZENECA LIMITED (GB) | 1997-10-14 | — | — | US | disclosed |
| EP-0739891-A2 | Substituted heterocycles | ZENECA LIMITED (GB) | 1996-10-30 | — | — | EP | disclosed |
| EP-0726893-A1 | NOVEL 4-PIPERIDINYL SUBSTITUTED LACTAMES AS NEUROKININ 2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA | ZENECA LIMITED (GB) | 1996-08-21 | — | — | EP | disclosed |
| WO-1996024582-A1 | 5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1996-08-15 | — | — | WO | disclosed |
| US-5534525-A | Lactam derivatives | ZENECA LIMITED (GB) | 1996-07-09 | — | — | US | disclosed |
| WO-1995012577-A1 | NOVEL 4-PIPERIDINYL SUBSTITUTED LACTAMES AS NEUROKININ 2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA | ZENECA LIMITED (GB) | 1995-05-11 | — | — | WO | disclosed |